heart
failur
remain
common
caus
death
disabl
major
econom
burden
industri
nation
physiolog
pharmacolog
clinic
studi
demonstr
activ
reninangiotensin
system
key
mediat
heart
failur
progress
angiotensin
convert
enzym
homologu
ace
monocarboxypeptidas
convert
angiotensin
ii
ang
ii
angiotensin
ang
virtu
action
ma
receptor
oppos
molecular
cellular
effect
ang
ii
wide
express
cardiomyocyt
cardiofibroblast
coronari
endotheli
cell
recent
preclin
translat
studi
confirm
critic
counterregulatori
role
axi
activ
reninangiotensin
system
result
heart
failur
preserv
eject
fraction
loss
enhanc
suscept
heart
failur
increas
level
prevent
revers
heart
failur
phenotyp
ang
emerg
key
protect
pathway
heart
failur
reduc
preserv
eject
fraction
recombin
human
test
phase
ii
clinic
trial
without
advers
effect
lower
increas
plasma
ang
ii
ang
level
respect
review
discuss
transcript
posttranscript
regul
role
axi
cardiac
physiolog
pathophysiolog
heart
failur
pharmacolog
therapeut
potenti
enhanc
action
novel
therapi
heart
failur
highlight
angiotensin
ii
angiotensin
angiotensin
angiotensin
convert
enzym
heart
failur
recombin
human
reninangiotensin
system
ra
peptiderg
system
function
homeostat
control
cardiovascular
renal
system
regul
extracellular
fluid
volum
inhibit
ra
play
central
role
allevi
increas
morbid
mortal
patient
heart
failur
hf
ra
consist
seri
enzymat
reaction
result
gener
angiotensin
ang
ii
first
step
renin
aspartyl
proteinas
secret
kidney
circul
cleav
hepat
peptid
angiotensinogen
produc
ang
blood
ang
hydrolyz
angiotensinconvert
enzym
ace
second
step
produc
octapeptid
ang
ii
biolog
activ
peptid
act
ang
ii
type
type
receptor
r
r
figur
ang
ii
promot
vasoconstrict
inflamm
salt
water
reabsorpt
oxid
stress
via
activ
r
detriment
effect
ang
iiat
r
encourag
quest
counterregulatori
axi
activ
ra
ra
initi
thought
function
system
entiti
local
specif
tissu
howev
notion
system
ra
challeng
observ
mani
tissu
capabl
synthes
key
compon
ra
includ
heart
kidney
vasculatur
pancrea
retina
brain
other
local
ra
could
produc
peptid
tissu
level
show
autocrin
effect
cell
produc
paracrin
effect
neighbor
cell
endocrin
effect
distant
organ
tissu
via
system
circul
concept
ra
famili
seen
substanti
chang
identif
angiotensinconvert
enzym
homologu
ace
monocarboxypeptidas
degrad
ang
nonapeptid
ang
ang
ii
heptapeptid
ang
figur
discoveri
ang
ang
unravel
distinct
enzymat
pathway
degrad
ang
ang
ii
endogen
neg
regul
ra
activ
moreov
identifi
import
ra
regul
capabl
mitig
deleteri
action
mediat
ang
ii
r
particular
import
patholog
condit
ra
activ
ang
biolog
activ
peptid
exert
wide
array
action
mani
opposit
attribut
ang
ii
endogen
orphan
receptor
ma
masr
identifi
ang
receptor
masr
antagonist
shown
block
major
ang
effect
ang
also
shown
benefici
biolog
effect
via
r
result
cardioprotect
thu
aceang
ii
r
wellestablish
axi
ra
r
axe
emerg
physiolog
antagonist
counterregul
activ
ra
taken
togeth
cardioprotect
effect
attribut
degrad
ang
ang
limit
avail
substrat
ace
action
ii
degrad
ang
ii
limit
detriment
effect
iii
gener
ang
exert
cardioprotect
effect
sever
line
evid
suggest
level
andor
activ
balanc
two
differ
arm
decreas
activ
result
activ
ang
iiat
r
axi
contribut
increas
progress
heart
diseas
increas
levelact
lead
activ
axe
lead
protect
heart
diseas
figur
review
highlight
role
counterregul
ang
ii
action
differ
approach
manipul
level
potenti
enhanc
action
therapi
hf
discoveri
biochemistri
regul
discoveri
differ
ace
ace
homologu
aceh
discov
zinc
metalloproteinas
two
differ
group
initi
identifi
human
hf
lymphoma
cdna
librari
later
shown
serv
receptor
sar
coronaviru
found
possess
appar
signal
peptid
transmembran
domain
singl
metalloproteinas
activ
site
contain
hexxh
zincbind
domain
type
transmembran
protein
extracellular
ntermin
domain
contain
catalyt
site
intracellular
ctermin
tail
similar
ace
catalyt
site
expos
ectoenzym
circul
vasoact
peptid
express
solubl
truncat
form
cho
cell
produc
glycoprotein
kda
abl
cleav
ang
ii
bradykinin
critic
residu
typic
ace
famili
conserv
tipni
et
al
discov
gene
contain
exon
sever
consider
size
similar
first
exon
human
ace
metalloproteinas
catalyt
domain
ace
ident
accord
find
donoghu
et
al
spite
similar
though
unlik
ace
convert
ang
ang
ii
fact
activ
inhibit
edta
unaffect
ace
inhibitor
captopril
lisinopril
research
reveal
major
differ
enzymat
action
ace
ace
act
dipeptidyl
carboxypeptidas
remov
dipeptid
cterminu
substrat
wherea
act
monocarboxypeptidas
remov
singl
amino
acid
degrad
ang
gener
nonapeptid
ang
ang
ii
gener
heptapeptid
ang
later
studi
focus
purif
character
catalyt
activ
show
ph
optimum
enhanc
activ
monoval
anion
includ
cl
f
br
consist
activ
ace
howev
later
shown
possess
one
cl
bind
site
compar
two
cl
site
ace
biolog
peptid
test
use
lcm
hydrolyz
three
peptid
high
effici
ang
ii
dynorphin
also
show
prefer
cleav
ctermin
amino
acid
peptid
end
prox
x
hydrophob
amino
acid
cleavag
prefer
support
key
experi
dipeptid
proph
complet
inhibit
activ
ang
ii
substrat
search
activ
site
residu
sitedirect
mutagenesi
reveal
critic
substrat
bind
replac
caus
complet
loss
enzym
activ
inhibitor
design
synthes
via
substratebas
structurebas
pharmacophor
design
virtual
screen
potent
select
inhibitor
develop
substratebas
design
key
tool
vivo
vitro
studi
last
year
distinct
role
discov
rang
catalyt
activ
variou
substrat
function
sar
coronaviru
receptor
amino
acid
transport
initi
thought
express
heart
kidney
test
eventu
found
wide
express
variou
organ
system
includ
cardiovascular
system
kidney
lung
brain
exert
import
action
maintain
cardiovascular
homeostasi
heart
local
cardiomyocyt
contract
cardiac
muscl
cell
cardiac
fibroblast
coronari
vascular
endothelium
masr
also
present
cardiomyocyt
cardiac
fibroblast
endotheli
cell
b
proteolyt
process
transcript
posttranscript
regul
variou
molecul
shed
cell
surfac
action
disintegrin
metalloproteinas
adam
also
known
tumor
necrosi
convert
enzym
tace
proteolysi
releas
enzymat
activ
ectodomain
cell
surfac
gener
solubl
activ
form
enzym
lambert
et
al
confirm
ectodomain
shed
heterolog
express
cell
endogen
express
cell
small
interf
rna
sirna
reduc
shed
overexpress
increas
provid
direct
evid
ectodomain
shed
lambert
et
al
later
discov
calmodulin
ubiquit
calcium
bind
protein
associ
prevent
shed
action
inhibit
calmodulin
inhibitor
howev
increas
shed
mediat
calmodulin
inhibitor
partial
block
metalloproteinas
inhibitor
suggest
involv
altern
proteolyt
pathway
yet
identifi
initi
observ
shed
confirm
shown
constitut
regul
phenomenon
variou
cell
type
includ
cho
cell
fibroblast
adipocyt
neuron
cardiomyocyt
proxim
tubular
cell
particular
identifi
posit
feedback
mechan
ra
wherebi
ang
ii
facilit
loss
neg
regul
ang
ii
action
r
lead
phosphoryl
mediat
mitogenactiv
protein
kinas
mapk
activ
result
increas
shed
figur
shed
membranebound
like
respons
loss
myocardi
elev
plasma
activ
hf
correl
worsen
prognosi
biolog
clinic
signific
ectodomain
shed
yet
fulli
character
inhibit
ectodomain
shed
manipul
enzym
activ
could
therapeut
potenti
hf
report
system
use
transcript
use
determin
function
put
microrna
mirna
bind
site
identifi
vitro
luciferas
report
assay
contain
strikingli
decreas
protein
level
loss
revers
effect
impli
modul
express
via
posttransl
repress
rather
degrad
mrna
transcript
identifi
potenti
regul
first
demonstr
posttranscript
regul
mrna
express
also
regul
sirtuin
energi
stress
hypoxia
adenosin
monophosph
kinas
ampk
activ
ribosid
aicar
increas
cellular
ratio
nad
nadh
increas
express
presenc
possibl
unknown
cofactor
bind
promot
region
bind
promot
aicar
aicarinduc
express
inhibit
inhibitor
provid
strong
evid
transcript
regul
condit
energi
stress
figur
similarli
apelin
also
increas
promot
activ
vitro
upregul
express
fail
heart
vivo
figur
therapeut
agent
increas
express
activ
apelin
inhibitor
neg
regul
tace
could
util
enhanc
activ
counteract
cardiovascular
diseas
includ
hf
heart
failur
grow
epidem
high
morbid
mortal
intern
scale
acut
chronic
hf
character
activ
sever
signal
pathway
associ
patholog
hypertrophi
maladapt
ventricular
remodel
hf
caus
damag
loss
cardiomyocyt
contribut
diminish
systol
perform
diastol
dysfunct
fail
heart
hf
involv
chang
cardiac
structur
myocardi
composit
myocyt
deform
multipl
biochem
molecular
alter
collect
refer
advers
myocardi
remodel
despit
improv
medic
surgic
therapi
cardiac
diseas
remain
lead
caus
death
north
america
ischem
hypertens
heart
diseas
lead
caus
hf
diabet
mellitu
obes
major
caus
morbid
mortal
part
world
includ
north
america
diabet
mellitu
character
insulin
insuffici
frequent
associ
sever
cardiovascular
complic
increas
risk
hypertens
hf
myocardi
infarct
mi
obes
independ
risk
factor
develop
hf
preserv
eject
fraction
hfpef
independ
comorbid
condit
rise
global
tide
obes
diabet
like
contribut
increas
preval
systol
diastol
hf
although
mechan
underli
intertwin
relationship
among
diabet
obes
hypertens
cardiovascular
event
remain
fulli
defin
major
culprit
implic
cardiovascular
inflamm
oxid
stress
mitochondri
dysfunct
insulin
resist
close
link
abnorm
ra
neurohormon
chang
activ
ra
increas
ang
ii
level
play
pivot
role
advers
myocardi
remodel
progress
hf
inde
pharmacolog
antagon
ra
use
ace
inhibitor
acei
r
blocker
arb
cornerston
current
medic
therapi
human
hf
includ
diabet
cardiomyopathi
pharmacotherapi
hf
provid
benefit
patient
hf
continu
plagu
clinic
deterior
high
morbid
mortal
irrespect
capac
ace
inhibitor
inhibit
ace
action
ang
ii
level
remain
elev
optim
treat
hf
patient
patient
use
ongo
acei
therapi
exhibit
elev
level
ang
ii
result
activ
mast
cell
chymas
therefor
urgent
need
identifi
altern
strategi
minim
detriment
effect
ang
ii
treat
hf
virtu
action
ang
ang
ii
natur
endogen
ace
inhibitor
cellular
level
figur
ang
product
degrad
ang
recent
shown
promis
antihypertroph
antifibrot
antihypertens
effect
benefici
effect
result
cardioprotect
hypertens
mi
adenovir
deliveri
ang
cardiomyocyt
shown
antihypertroph
effect
compar
adenovir
ang
deliveri
moreov
rhoarho
kinas
inhibit
shown
potent
antihypertens
effect
mediat
via
upregul
vascular
plasma
increas
plasma
ang
level
without
increas
ang
level
suggest
potenti
role
ang
antihypertens
effect
rhoarhokinas
inhibit
ang
ang
ii
function
prefer
substrat
studi
use
recombin
human
purifi
sheep
tissu
show
ang
ii
prefer
substrat
sheep
convers
ang
ang
detect
proxim
tubul
contain
robust
activ
convert
ang
ii
ang
contrast
chang
correl
plasma
ang
level
rat
recent
studi
ye
et
al
demonstr
gener
ang
ang
recombin
murin
gener
predominantli
ang
addit
therapeut
effect
highli
depend
ang
action
rodent
human
studi
clearli
lower
plasma
ang
ii
level
result
increas
plasma
ang
level
howev
remain
possibl
contribut
ang
benefici
effect
may
underestim
requir
investig
clear
emphasi
human
studi
ang
activ
masr
exert
variou
effect
major
antagon
ang
ii
effect
effect
includ
activ
phosphatidylinositol
aktendotheli
nitric
oxid
synthas
eno
pathway
ii
inhibit
protein
kinas
c
pkc
mapk
pathway
iii
inhibit
collagen
express
limit
cardiac
fibrosi
figur
understand
rel
contribut
inhibit
ang
iiat
r
axi
activ
ang
axi
cardioprotect
effect
studi
effect
irbesartan
ang
supplement
pressureoverloadinduc
hf
knockout
mice
found
function
redund
antifibrot
antihypertroph
effect
suppress
patholog
signal
cardioprotect
effect
irbesartan
ang
equival
suggest
similar
signific
axe
activ
ra
ang
ii
establish
key
mediat
hypertens
therefor
hypothes
potent
modul
blood
pressur
defici
lead
hypertens
preclin
model
hypertens
gene
map
defin
quantit
trait
locu
xchromosom
previous
identifi
quantit
locu
blood
pressur
recent
studi
suggest
associ
activ
blood
pressur
level
serum
activ
higher
patient
hypertens
compar
healthi
individu
hypertens
patient
type
diabet
serum
activ
posit
correl
systol
blood
pressur
male
femal
studi
suggest
elev
may
compensatori
respons
hypertens
inde
antihypertens
role
also
establish
variou
preclin
model
hypertens
lentivir
overexpress
result
increas
express
antihypertens
compon
ra
ang
masr
r
attenu
elev
blood
pressur
similarli
pretreat
allevi
hypertens
induc
acut
ang
ii
infus
associ
decreas
plasma
ang
ii
increas
plasma
ang
level
cyclodextrinencapsul
ang
masr
agonist
shown
blood
pressurelow
effect
hypertens
anim
antihypertens
effect
gener
interest
potenti
cardioprotect
effect
hypertens
heart
diseas
group
disord
includ
hf
ischem
heart
diseas
hypertens
heart
diseas
left
ventricular
hypertrophi
play
critic
role
control
cardiac
physiolog
alter
express
activ
link
progress
heart
diseas
figur
heart
express
variou
cell
includ
cardiomyocyt
cardiac
fibroblast
coronari
endotheli
cell
negat
ang
ii
action
also
activ
ang
signal
figur
express
highli
affect
patholog
diseas
condit
suggest
role
counterregul
develop
cardiac
diseas
human
popul
genet
variat
gene
correl
suscept
cardiovascular
diseas
singl
nucleotid
polymorph
associ
variat
septal
wall
thick
ventricular
hypertrophi
coronari
arteri
diseas
first
report
role
essenti
regul
cardiac
function
came
soon
discoveri
studi
knockout
mice
show
reduc
systol
function
decreas
systol
function
sexand
timedepend
sever
abnorm
male
femal
mice
pronounc
phenotyp
older
anim
knockout
mice
also
show
increas
ang
ii
level
rescu
genet
ablat
ace
consist
found
agedepend
dilat
cardiomyopathi
knockout
mice
result
reduc
systol
function
along
increas
cardiac
inflamm
oxid
stress
myocardi
protein
level
decreas
pressureoverloadinduc
hf
suggest
invers
relationship
myocardi
protein
level
diseas
progress
addit
loss
result
worsen
patholog
remodel
respons
pressureoverloadinduc
biomechan
stress
associ
systol
dysfunct
ventricular
dilat
deem
due
activ
myocardi
napdh
oxidas
system
superoxid
product
matrix
metalloproteinas
mmp
activ
attribut
increas
local
ang
ii
level
figur
tabl
postmi
remodel
coronari
arteri
diseas
one
common
caus
hf
mi
increas
mrna
express
human
mice
rat
wherea
loss
inhibit
result
worsen
miinduc
cardiac
dysfunct
increas
infarct
size
mmp
activ
cardiac
extracellular
matrix
disrupt
inflamm
tabl
lentivir
adenovir
overexpress
amelior
miinduc
cardiac
remodel
addit
lentivir
infect
cultur
fibroblast
decreas
acut
hypox
exposureinduc
product
collagen
importantli
ang
treatment
shown
notic
cardioprotect
effect
preclin
model
nonischem
ischem
cardiomyopathi
ang
suppress
cardiomyocyt
growth
vitro
inhibit
myocardi
infarctioninduc
ventricular
hypertrophi
vivo
ang
also
decreas
myocardi
level
proinflammatori
cytokin
lead
allevi
cardiac
inflamm
result
confirm
import
contribut
ang
cardioprotect
effect
figur
hfpef
also
term
diastol
hf
often
associ
normal
smaller
heart
size
diastol
fill
abnorm
account
approxim
hf
patient
similar
mortal
rate
patient
hfref
ang
iiinduc
diastol
dysfunct
clinic
relev
wide
accept
preclin
model
hfpef
other
found
loss
result
worsen
cardiac
dysfunct
cardiac
hypertrophi
fibrosi
lead
greater
diastol
dysfunct
respons
ang
ii
tabl
importantli
treatment
decreas
plasma
myocardi
ang
ii
level
increas
plasma
ang
level
provid
definit
evid
key
role
metabol
ang
ii
furthermor
attenu
patholog
chang
mediat
ang
ii
reduc
myocardi
hypertrophi
fibrosi
correct
diastol
dysfunct
howev
treatment
affect
baselin
plasma
ang
ii
ang
blood
pressur
wildtyp
mice
suggest
substrat
avail
limit
factor
enzymat
activ
pursuit
molecular
mechan
action
identifi
capac
inhibit
ang
ii
effect
activ
collagen
product
loss
also
result
increas
product
reactiv
oxygen
speci
ro
via
nadph
oxidas
activ
also
suppress
lentivir
overexpress
protect
heart
myocardi
injuri
induc
ang
ii
rat
confirm
role
counteract
hfpef
assess
contribut
ang
activ
favor
effect
shown
ang
iiinduc
murin
hf
model
inhibit
ang
signal
result
loss
mediat
cardioprotect
effect
howev
observ
rule
potenti
contribut
ang
protect
effect
appropri
preclin
studi
requir
assess
rel
contribut
ang
ang
endogen
regul
activ
rasinduc
hfpef
enhanc
mark
benefici
effect
diabet
obes
major
caus
morbid
mortal
part
world
includ
canada
studi
axi
diabet
obesityassoci
cardiac
dysfunct
shed
light
critic
role
pathway
counterregul
ang
iiat
r
axi
figur
human
type
diabet
elev
plasma
activ
correl
microvascular
macrovascular
complic
increas
systol
blood
pressur
durat
diabet
strongli
support
key
clinic
role
system
cardiovascular
diseas
secondari
diabet
role
diabet
cardiovascular
complic
studi
variou
preclin
model
diabet
tool
knockout
mice
adenovir
gene
transfer
activ
inhibitor
ang
supplement
ang
masr
activ
ang
receptor
blockad
util
assess
role
diabet
cardiovascular
complic
studi
role
prevent
progress
type
diabet
cardiovascular
complic
use
clinic
relev
anim
model
diabet
akita
mous
akita
type
diabet
heart
show
diastol
dysfunct
associ
reduc
level
cardiac
increas
myocardi
lipotox
loss
heart
knockout
doubl
mutant
result
systol
dysfunct
knockout
heart
exhibit
increas
nadph
oxidas
activ
ro
product
protein
kinas
c
mmp
activ
lead
increas
degrad
cardiac
extracellular
matrix
studi
demonstr
key
role
neg
regul
activ
ra
diabet
cardiomyopathi
studi
valid
find
essenti
role
diabet
cardiomyopathi
also
identifi
benefici
effect
ang
type
diabet
cardiomyopathi
reduc
cardiac
hypertrophi
lipotox
adipos
inflamm
combin
increas
adipos
triglycerid
lipas
ang
complet
rescu
diastol
dysfunct
dbdb
type
diabet
murin
model
obes
character
excess
fat
accumul
adipos
tissu
throughout
bodi
common
nutrit
disord
industri
countri
obes
associ
increas
morbid
mortal
risk
factor
develop
hfpef
independ
comorbid
condit
studi
role
obes
induc
high
fat
diet
associ
cardiac
dysfunct
loss
associ
worsen
obesityassoci
hfpef
due
increas
epicardi
adipos
tissu
inflamm
myocardi
lipotox
cardiac
metabol
abnorm
tabl
find
coupl
protect
effect
vasculatur
support
key
role
adipos
tissu
inflamm
microvascular
dysfunct
pathogenesi
hfpef
importantli
ang
prevent
chang
rescu
hfpef
knockout
mice
valid
critic
role
cardioprotect
figur
enhanc
pathway
repres
potenti
therapi
hfpef
current
lack
effect
therapi
irrespect
capac
acei
inhibit
ace
action
ang
ii
level
remain
elev
optim
treat
hf
patient
patient
use
ongo
acei
therapi
exhibit
elev
level
ang
ii
gener
plasma
tissu
ang
ii
nonac
relat
enzym
chymas
suggest
enhanc
action
may
inde
uniqu
therapeut
role
fact
acei
arb
shown
upregul
express
prevent
loss
shed
repres
mechan
ang
ii
induc
posit
feedback
mechan
tissueloc
ra
lead
dysregul
result
neurohumor
imbal
typic
hf
inhibit
tacemedi
shed
surfac
cardiac
cell
lead
retent
enzymat
activ
within
cardiac
microenviron
might
therapeut
potenti
posttranscript
regul
inhibit
may
result
increas
express
also
subject
transcript
regul
apelin
activ
apelin
may
therapeut
benefit
enhanc
action
wellstudi
tool
enhanc
action
random
doubleblind
placebocontrol
studi
administ
intraven
healthi
human
subject
found
welltoler
despit
mark
chang
angiotensin
system
peptid
concentr
hypotens
absent
suggest
presenc
effect
compensatori
mechan
healthi
volunt
primarili
respons
convers
ang
ii
ang
also
convert
ang
ang
healthi
human
volunt
treat
ang
ii
level
reduc
ang
level
increas
remain
unchang
importantli
recent
complet
phase
ii
trial
patient
acut
lung
injuri
result
sustain
reduct
plasma
ang
ii
level
elev
ang
level
propos
assess
plasma
ra
peptid
level
allow
tailor
therapi
human
hf
provid
benefici
effect
ang
iiinduc
hfpef
pressureoverloadinduc
hfref
murin
model
hf
tabl
thu
use
therapi
much
viabl
option
advanc
clinic
trial
provid
translat
impact
find
murin
model
sever
activ
ang
agonist
develop
addit
novel
approach
includ
oral
ang
biencapsul
plant
cell
design
use
preclin
studi
show
promis
cardioprotect
effect
lastli
gene
therapi
approach
could
util
achiev
tissuespecif
deliveri
autolog
cellbas
therapi
use
put
progenitor
cell
cell
could
attract
therapeut
approach
diabet
vascular
complic
howev
cell
dysfunct
diabet
individu
peripher
cell
isol
patient
diabet
exhibit
reduc
prolif
potenti
migratori
function
could
attribut
decreas
eno
activ
increas
ro
level
advanc
glycat
endproduct
ang
potent
activ
eno
antioxid
axi
improv
cell
function
result
increas
repar
efficaci
inde
ang
increas
vascular
repar
function
cell
isol
patient
diabet
emerg
domin
mechan
neg
regul
ra
metabol
ang
ii
benefici
peptid
ang
import
biochem
physiolog
properti
har
potenti
therapi
hf
sinc
discoveri
tremend
progress
made
elucid
biochem
action
key
role
heart
diseas
hf
wide
express
regul
fundament
cellular
biolog
cardiomyocyt
cardiofibroblast
coronari
endotheli
cell
hfref
hfpef
model
ang
also
emerg
hf
model
physiolog
activ
peptid
protect
effect
enhanc
ang
action
may
also
provid
mark
therapeut
effect
hf
clinic
experiment
studi
clearli
support
physiolog
pathophysiolog
role
hf
studi
indic
increasingactiv
result
benefici
effect
prevent
heart
diseas
hf
experiment
studi
requir
combin
activ
ra
blocker
ace
inhibitor
r
blocker
determin
combin
approach
offer
addit
benefit
refer
web
version
pubm
central
supplementari
materi
express
transcript
regul
energi
stress
activ
ampk
via
bind
promot
region
facilit
mrna
express
similarli
apelin
bind
promot
region
enhanc
express
mrna
subject
posttranscript
regul
regul
protein
express
ang
ii
main
effector
peptid
ra
produc
ace
chymas
heart
tissu
monocarboxypeptidas
degrad
ang
ii
heptapetid
ang
ang
ii
via
action
r
promot
ro
format
lead
phosphoryl
activ
ultim
result
tace
phosphoryl
activ
activ
tace
proteolyt
cleav
releas
activ
ectodomain
ang
iiat
r
critic
involv
diseas
progress
lead
nonischem
ischem
diabet
cardiomyopathi
obesityassoci
cardiac
dysfunct
convert
ang
ii
ang
shift
balanc
cardioprotect
axi
eat
epicardi
adipos
tissu
intervent
modul
level
activ
effect
experiment
model
heart
failur
lentivir
overexpress
lad
coronari
arteri
ligat
week
postsurgeri
complet
rescu
cardiac
output
rescu
eject
fraction
rescu
contractil
rescu
lv
anterior
infract
wall
thin
compar
control
rat
lentivir
overexpress
shr
attenu
high
blood
pressur
shr
reduct
left
ventricular
wall
thick
increas
left
ventricular
end
diastol
increas
end
systol
diamet
shr
attenu
perivascular
fibrosi
lentivir
overexpress
ang
ii
infus
attenu
increas
heart
weightbodi
weight
myocardi
fibrosi
induc
ang
ii
infus
lentivir
overexpress
cardiac
fibroblast
hypoxiareoxygen
attenu
basal
hypoxiareoxygenationinduc
collagen
product
fibroblast
adenovir
overexpress
lad
coronari
arteri
ligat
week
gene
transfer
reduc
lv
volum
extent
myocardi
fibrosi
increas
lv
eject
fraction
level
activ
ang
ii
infus
blunt
hypertroph
respons
express
hypertrophi
marker
decreas
ro
product
inhibit
patholog
signal
administr
wki
rat
reduc
ang
ii
infusioninduc
pressor
respons
myocardi
hypertrophi
patholog
signal
superoxid
product
shr
administr
partli
correct
hypertens
ro
product
patholog
signal
heart
transvers
aortic
constrict
partial
prevent
pressureoverloadinduc
dilat
cardiomyopathi
mrna
express
diseas
marker
profibrot
gene
activ
dize
lad
coronari
arteri
ligat
dize
attenu
miinduc
decreas
fraction
shorten
improv
dpdtmax
revers
ventricular
hypertrophi
